Originally published Jan. 16.

In a pharmacogenetic investigation conducted by researchers in the Netherlands, Bayer's Nexavar was not able to improve survival in patients with KRAS-mutated non-small cell lung cancer.

In the Phase II multicenter trial, researchers led by Wouter Mellema of VU University Medical Center in Amsterdam assigned 57 patients with NSCLC and a KRAS mutation to 400 mg of Nexavar (sorafenib) twice daily.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.